Date:1/24/2013

ntangible assets and licenses(1,233)(5,372)(1,233)(5,372)  Amortization of purchased intangible assets(332)(347)(1,330)(1,383)Non-GAAP measure of cost of product sales$ 40,523$ 32,470$ 147,765$ 114,401Gross margin on product sales per GAAP52%50%52%54%Gross margin on product sales per Non-GAAP55%58%54%57%Operating expenses$ 43,063$ 41,293$ 176,878$ 146,057  Stock compensation expense(5,756)(4,806)(21,415)(18,084)  Impairment of intangible assets and licenses(328)-(328)-  Amortization of purchased intangible assets(376)(107)(1,452)(429)Non-GAAP measure of operating expenses$ 36,603$ 36,380$ 153,683$ 127,544Income (loss) from operations$   5,058$ (1,393)$ (21,324)$
3,815  Stock compensation expense6,5645,24924,45219,768  Amortization of purchased intangible assets7084542,7821,812  Impairment of intangible assets and licenses1,5615,3721,5615,372  Litigation settlement--15,110-Non-GAAP measure of income from operations$ 13,891$   9,682$   22,581$   30,767Net income (loss)$   5,644$ (1,649)$ (20,043)$
2,627  Stock compensation expense6,5645,24924,45219,768  Amortization of purchased intangible assets7084542,7821,812  Impairment of intangible assets and licenses, net of tax1,2885,3721,2885,372  Litigation settlement--15,110-  Tax benefit related to intercompany IP transaction--(1,815)-Non-GAAP measure of net income$ 14,204$   9,426$   21,774$   29,579Basic net income (loss) per share$
.09$   (0.03)$
(0.30)$
.04  Stock compensation expense0.090.080.370.32  Amortization of purchased intangible assets0.010.010.040.03  Impairment of intangible assets and licenses, net of tax0.020.090.020.08  Litigation settlement--0.23-  Tax benefit related to intercompany IP transaction--(0.03)-Non-GAAP measure of net income per share$
.21$
.15$
.33$
.47Diluted net income (loss) per share$
.08$   (0.03)$
(0.30)$
.04
'/>"/>

SOURCE Cepheid Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related medicine technology :

1. Cepheid to Webcast Upcoming Financial Presentations
2. Cepheid Announces Executive Vice President Emerging Markets
3. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
4. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
5. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
6. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
7. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
8. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
9. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
10. Luminex Corporation Reports First Quarter 2012 Results
11. Hospira Reports First-Quarter 2012 Results